Usefulness of autotaxin for the complications of liver cirrhosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
      Original Publication: Beijing : WJG Press, c1998-
    • Subject Terms:
      Severity of Illness Index*; Ascites/*diagnosis ; Hepatic Encephalopathy/*diagnosis ; Liver Cirrhosis/*blood ; Phosphoric Diester Hydrolases/*blood; Aged ; Area Under Curve ; Ascites/etiology ; Biomarkers/blood ; Female ; Hepatic Encephalopathy/etiology ; Humans ; Japan ; Liver/pathology ; Liver Cirrhosis/complications ; Male ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies
    • Abstract:
      Background: Autotaxin (ATX) has been reported as a direct biomarker for estimating the evaluation of liver fibrosis. But available data on ATX as a useful biomarker for the complications of liver cirrhosis (LC) are scant.
      Aim: To assess the clinical usefulness of ATX for assessing the complications of LC.
      Methods: This multicenter, retrospective study was conducted at six locations in Japan. We include patients with LC, n = 400. The ATX level was evaluated separately in men and women because of its high level in female patients. To assess the clinical usefulness of ATX for the complications of LC, the area under the curve (AUC) of ATX assessing for the severe complications was analyzed in comparison with the model for end-stage liver disease score, albumin-bilirubin (ALBI) score, fibrosis-4 index, and aspartate aminotransferase-to-platelet ratio index.
      Results: The mean age was 68.4 ± 11.4 years, 240 patients (60.0%) were male. A total of 213 (53.3%) and 187 (46.8%) patients were compensated and decompensated, respectively. The numbers of patients with varix rupture, hepatic ascites, and hepatic encephalopathy were 35 (8.8%), 131 (32.8%), and 103 (25.8%), respectively. The AUCs of ATX in men for hepatic encephalopathy, hepatic ascites, and varix ruptures were 0.853, 0.816, and 0.706, respectively. The AUCs of ATX in women for hepatic encephalopathy, hepatic ascites, and varix rupture were 0.759, 0.717, and 0.697, respectively. The AUCs of ATX in men were higher than those in women, as were all the other biomarkers used to detect encephalopathy and varix ruptures. However, for detecting ascites, the AUC of ALBI in men was more effective than using ATX.
      Conclusion: ATX in men was more effective than any other biomarkers for detecting hepatic encephalopathy and varix ruptures.
      Competing Interests: Conflict-of-interest statement: We have no financial relationships to disclose.
      (©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.)
    • References:
      J Biol Chem. 2004 Apr 23;279(17):17634-9. (PMID: 14744855)
      Hepat Med. 2019 Jan 25;11:23-34. (PMID: 30774483)
      Clin Chim Acta. 2011 Jun 11;412(13-14):1201-6. (PMID: 21419756)
      PLoS One. 2014 Jul 25;9(7):e103532. (PMID: 25062038)
      Curr Drug Targets. 2016;17(15):1804-1817. (PMID: 27296314)
      J Biol Chem. 2006 Sep 1;281(35):25822-30. (PMID: 16829511)
      J Gastroenterol Hepatol. 2016 May;31(5):1031-6. (PMID: 26647219)
      J Biol Chem. 1992 Feb 5;267(4):2524-9. (PMID: 1733949)
      J Gastroenterol Hepatol. 1994 Nov-Dec;9(6):624-30. (PMID: 7532451)
      J Community Hosp Intern Med Perspect. 2017 Mar 31;7(1):8-14. (PMID: 28634518)
      Gut. 2002 Apr;50(4):571-81. (PMID: 11889082)
      Ann Gastroenterol. 2012;25(3):218-231. (PMID: 24714123)
      Hepatology. 2017 Jan;65(1):310-335. (PMID: 27786365)
      Hepatology. 2009 Mar;49(3):1017-44. (PMID: 19243014)
      Liver Int. 2010 Apr;30(4):546-53. (PMID: 20074094)
      Clin Biochem. 2016 Feb;49(3):302-15. (PMID: 26188920)
      J Cell Biol. 1996 Nov;135(4):1071-83. (PMID: 8922387)
      J Gastroenterol. 2015 Jan;50(1):76-84. (PMID: 24603981)
      Gastroenterology. 1988 Jun;94(6):1493-502. (PMID: 3360270)
      J Clin Exp Hepatol. 2013 Mar;3(1):50-60. (PMID: 25755471)
      J Biol Chem. 2002 Oct 18;277(42):39436-42. (PMID: 12176993)
      Mol Cell Biol. 2006 Jul;26(13):5015-22. (PMID: 16782887)
      N Engl J Med. 2016 Aug 25;375(8):767-77. (PMID: 27557303)
      Nat Rev Cancer. 2003 Aug;3(8):582-91. (PMID: 12894246)
      Cancer Lett. 2009 Nov 1;284(2):216-21. (PMID: 19482419)
      Clin Biochem. 2007 Feb;40(3-4):274-7. (PMID: 17222397)
      Hepatol Commun. 2018 Aug 23;2(9):1111-1122. (PMID: 30202824)
    • Contributed Indexing:
      Keywords: Autotaxin; Biomarker; Hepatic ascites; Hepatic encephalopathy; Liver fibrosis
    • Accession Number:
      0 (Biomarkers)
      EC 3.1.4.- (Phosphoric Diester Hydrolases)
      EC 3.1.4.39 (alkylglycerophosphoethanolamine phosphodiesterase)
    • Publication Date:
      Date Created: 20200115 Date Completed: 20201019 Latest Revision: 20201019
    • Publication Date:
      20240628
    • Accession Number:
      PMC6952300
    • Accession Number:
      10.3748/wjg.v26.i1.97
    • Accession Number:
      31933517